通化東寶(600867.SH)業績預告更正：預計2024年淨利潤同比減少約99%
格隆匯2月26日丨通化東寶(600867.SH)公佈2024年年度業績預告更正公告，公司於2025年1月21日披露了《通化東寶2024年年度業績預減公告》。前次業績預告具體情況如下：預計2024年年度實現歸屬於上市公司股東的淨利潤約爲4,052.77萬元，與上年同期相比，將減少約112,730.76萬元，同比減少約96.53%。實現歸屬於上市公司股東的扣除非經常性損益的淨利潤約爲27,071.92萬元，與上年同期相比，將減少約89,679.41萬元，同比減少約76.81%。
更正後的業績預告情況：經財務部門再次測算，預計2024年年度實現歸屬於上市公司股東的淨利潤約爲1,164.21萬元，與上年同期相比，將減少約115,619.32萬元，同比減少約99.00%。預計2024年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤約爲26,354.25萬元，與上年同期相比，將減少約90,397.08萬元，同比減少約77.43%。
2021年1月，甘李藥業股份有限公司在江蘇省蘇州市中級人民法院起訴公司及蘇州雷允上國藥連鎖總店有限公司生產銷售的“長舒霖”甘精胰島素侵害其“長秀霖”商標權並構成不正當競爭。在經歷江蘇省蘇州市中級人民法院和江蘇省高級人民法院一審和二審審判後，公司近日收到江蘇省高級人民法院送達的終審《民事判決書》<（2022）蘇民終1604號>。根據該判決書，公司應賠償甘李藥業經濟損失60,000,000元及維權合理開支816,238.80元，並補償甘李藥業承擔的一審訴訟費495,881.19元，共計61,312,125.99元。對於上述事項，公司在收到終審《民事判決書》之前，預計賠付金額約爲3,000萬元，並按3,000萬元確認了相關負債及損失。收到終審《民事判決書》後，公司按應賠付金額與之前預計賠付金額的差額部分補充確認了相關負債及損失。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
